CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsHuibin Tang, Joseph B. Shrager
Life of this patent
Estimating the term…
Abstract
The invention relates to a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas guide RNA (gRNA) comprising a targeting domain that is complementary to human genomic Epidermal Growth Factor Receptor (EGFR) DNA, and a vector system including one or more packaged vector(s) including: (a) a first regulatory element operably linked to a gRNA, and (b) a second regulatory element operably linked to a nucleic acid encoding a Cas protein. Also disclosed are methods of altering a nucleic acid sequence encoding EGFR in a cell including contacting the cell with a vector system, methods of treating lung cancer, and methods of selectively inducing apoptosis in a cell including administering a gRNA to the cell.
Claims14
A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas guide RNA (gRNA) comprising a targeting domain that is complementary to human genomic Epidermal Growth Factor Receptor (EGFR) DNA, wherein the targeting domain is configured to:
- (a) restore or destroy a wild type sequence at E746-A750 in exon 19,
- (b) restore or destroy a threonine residue at position 790 in exon 20, or
- (c) restore or destroy a leucine at position 858 in exon 21.
Dependencies are inferred from the claim text.